<?xml version="1.0" encoding="UTF-8"?>
<p id="Par15">Guillain–Barré syndrome (GBS) is one of the new complications and manifestations of ZIKV infection [
 <xref ref-type="bibr" rid="CR34">34</xref>]. GBS is a serious and life threatening neurological disorder eventually resulting in respiratory failure characterized by progressive muscular weakness [
 <xref ref-type="bibr" rid="CR55">55</xref>]. Outbreak of ZIKV in French Polynesia four years ago added it to the viruses that can trigger GBS [
 <xref ref-type="bibr" rid="CR56">56</xref>]. WHO estimated there could be 3 to 4 million cases of this infection in the following year, therefore, there is a probability of hundreds of cases of GBS. Sufficient intravenous (IV) immunoglobulin (Ig) treatment for patients with ZIKV related GBS should be applied [
 <xref ref-type="bibr" rid="CR57">57</xref>]. Increased verification of a ZIKV infection based on laboratory results and GBS prevalence have been reported in 12 countries. In 2015, 1708 GBS cases were recorded in Brazil, indicating a 19% escalation from the preceding year as 1439 GBS cases were reported in 2014. 62% of GBS cases reported in Brazil had a history of signs and symptoms associated to this viral infection. 220 cases of GBS are reported in Colombia while 136 in El Salvador including 5 deaths in the time period from December 2015 to March 2016 [
 <xref ref-type="bibr" rid="CR53">53</xref>].
</p>
